Results indicated that MYBL1 might be correlated with worse prognosis performance of ccRCC patients, including overall survival (OS), disease-free survival (DSS) and progression-free survival (PFI) in both TCGA and E-MTAB-1980 cohorts (Figures 1E, F). This evidence concerns the gene MYBL1 and nonpapillary renal cell carcinoma.